Non-small cell lung cancer.

Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KM, NCCN (National Comprehensive Cancer Network)
J Natl Compr Canc Netw. 2012 10 (10): 1236-71

PMID: 23054877 · DOI:10.6004/jnccn.2012.0130

Most patients with non-small cell lung cancer (NSCLC) are diagnosed with advanced cancer. These guidelines only include information about stage IV NSCLC. Patients with widespread metastatic disease (stage IV) are candidates for systemic therapy, clinical trials, and/or palliative treatment. The goal is to identify patients with metastatic disease before initiating aggressive treatment, thus sparing these patients from unnecessary futile treatment. If metastatic disease is discovered during surgery, then extensive surgery is often aborted. Decisions about treatment should be based on multidisciplinary discussion.

MeSH Terms (13)

Algorithms Biomarkers, Tumor Carcinoma, Non-Small-Cell Lung Clinical Laboratory Techniques Humans Lung Neoplasms Medical Oncology Molecular Diagnostic Techniques Neoplasm Metastasis Neoplasm Staging Practice Guidelines as Topic Prognosis Recurrence

Connections (1)

This publication is referenced by other Labnodes entities: